| Project/Area Number |
22300340
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (B)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Clinical oncology
|
|---|
| Research Institution | Kyoto University (2011-2012)
Nagasaki University (2010) |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
OZAKI Kei-ichi 長崎大学, 大学院・医歯薬学総合研究科, 准教授 (50252466)
TANIMURA Susumu 長崎大学, 大学院・医歯薬学総合研究科, 助教 (90343342)
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
UESATO Shin-ichi 関西大学, 工学部, 教授 (50111969)
|
|---|
| Project Period (FY) |
2010 – 2012
|
| Project Status |
Completed (Fiscal Year 2012)
|
| Budget Amount *help |
¥17,550,000 (Direct Cost: ¥13,500,000、Indirect Cost: ¥4,050,000)
Fiscal Year 2012: ¥3,250,000 (Direct Cost: ¥2,500,000、Indirect Cost: ¥750,000)
Fiscal Year 2011: ¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2010: ¥10,270,000 (Direct Cost: ¥7,900,000、Indirect Cost: ¥2,370,000)
|
|---|
| Keywords | 細胞がん化 / がん化学療法 / ERK-MAP キナーゼ経路 / MEK 阻害剤 / 微小管重合阻害剤 / HDAC 阻害剤 / 併用療法 / Bcl-2 ファミリー蛋白質 / ERK-MAPキナーゼ経路 / MEK阻害剤 / 微小管阻害剤 / HDAC阻害剤 / 動物個体系 |
|---|
| Research Abstract |
Specific blockade of the ERK pathway by MEK inhibitors alone induces mostly cytostatic rather than pro-apoptotic effects, resulting in a limited therapeutic efficacy of MEK inhibitors. However, MEK inhibitors specifically and markedly sensitize various humor tumor xenografts to microtubule-destabilizing agent-/HDAC inhibitor-induced cytotoxicity. Our results clearly indicate that administration of both a MEK inhibitor and a microtubule-destabilizing agent/HDAC inhibitor represents a promising chemotherapeutic strategy with improved safety for cancer patients.
|
